Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?
Cardiovascular complications are frequently observed in diabetic patients and are mostly caused by endothelial dysfunction associated with a decline in biosynthesis of nitric oxide (NO). In response to this concern, a remarkable increase in the interest for development of NO-releasing hybrid drugs has been observed. The NO-donating entity was linked to known drugs with the belief that NO is a vasorelaxant and an inhibitor of platelet aggregation or reduces thrombotic events. Many of these NO-releasing hybrid drugs have shown significant improvement in cardiovascular safety. In this editorial the potential roles of NO-releasing drugs for the treatment of cardiovascular complications in diabetes will be discussed.
Department of Oncology, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
Atul
A
Bhardwaj
Jatinder
J
Kaur
Frank
F
Wuest
Edward E
EE
Knaus
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D012307:Risk Factors
D020030:Nitric Oxide Donors; D009569:Nitric Oxide